26.08
0.00 (0.00%)
| Penutupan Terdahulu | 26.08 |
| Buka | 25.88 |
| Jumlah Dagangan | 1,371,905 |
| Purata Dagangan (3B) | 1,818,213 |
| Modal Pasaran | 2,656,410,880 |
| Harga / Jualan (P/S) | 17.43 |
| Harga / Buku (P/B) | 2.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Operasi (TTM) | -1,596.87% |
| EPS Cair (TTM) | -4.61 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 0.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.08% |
| Nisbah Semasa (MRQ) | 8.81 |
| Aliran Tunai Operasi (OCF TTM) | -351.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -185.90 M |
| Pulangan Atas Aset (ROA TTM) | -19.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -38.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Beam Therapeutics Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.38 |
|
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.22% |
| % Dimiliki oleh Institusi | 98.07% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mwg Management Ltd. | 30 Sep 2025 | 2,266,934 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 74.00 (Canaccord Genuity, 183.74%) | Beli |
| Median | 41.00 (57.21%) | |
| Rendah | 26.00 (RBC Capital, -0.31%) | Pegang |
| Purata | 46.80 (79.45%) | |
| Jumlah | 3 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 29.37 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 25 Feb 2026 | 26.00 (-0.31%) | Pegang | 29.61 |
| Wedbush | 25 Feb 2026 | 65.00 (149.23%) | Beli | 29.61 |
| Canaccord Genuity | 20 Feb 2026 | 74.00 (183.74%) | Beli | 27.59 |
| Bernstein | 21 Jan 2026 | 41.00 (57.21%) | Beli | 31.12 |
| UBS | 07 Jan 2026 | 28.00 (7.36%) | Pegang | 28.93 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |